Nuformix Research Results News

Nuformix Publishes Positive Fibrofind Results

On January 31st, Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme.

This pilot study has been performed by FibroFind the University-based service facility embedded in Newcastle Fibrosis Research Group

Click HERE to download the report published by Nuformix

Author Jeremy Domis

Last modified: Tue, 13 Feb 2018 14:52:13 GMT